US EditionDEA Delays MMJ Cannabis Research While Allowing Texas Ibogaine Studies Without Obstruction: The Tale of Two Schedule I Substances
Summary by ecnetnews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
DEA Delays MMJ Cannabis Research While Allowing Texas Ibogaine Studies Without Obstruction: The Tale of Two Schedule I Substances
Two Schedule I drugs. Two research tracks. One DEA double standard.MMJ BioPharma Cultivation's FDA sanctioned cannabis research has been stonewalled for seven years. Meanwhile, Texas launches state-funded ibogaine trials with full political support and zero DEA obstruction.Is federal drug policy about science or selective enforcement? WASHINGTON, DC, June 15, 2025 (Ecnetnews.com) - The Drug Enforcement
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
